Company / Financials
Ovid Therapeutics Inc. Financials
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$566.0K
FY2025 · +44.4% YoY
Net Income
-$26.4M
FY2025 · +49.5% YoY
Profit Margin
-4670.1%
FY2025 · net income / revenue
ROE
-38.7%
FY2025 · return on equity
Total Assets
$150.9M
FY2025
Total Debt
-
FY2025
Equity
$68.2M
FY2025
ROA
-17.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$566.0K+44.4% YoYNet Income HistoryProfit after all expenses and taxes-$26.4M+49.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$61.9M-4.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$25.7M-17.4% YoYR&D Expense HistoryResearch and development spending$36.8M+28.6% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-Shares Outstanding HistoryWeighted average diluted shares outstanding71.0M+0.4% YoYTotal Assets HistoryTotal value of all assets owned$150.9M+63.8% YoY